Adherence to early antiretroviral therapy: Results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples

Steven Safren, Kenneth H. Mayer, San San Ou, Marybeth McCauley, Beatriz Grinsztejn, Mina C. Hosseinipour, Nagalingeswaran Kumarasamy, Theresa Gamble, Irving Hoffman, David Celentano, Ying Qing Chen, Myron S. Cohen

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Background: Combination antiretroviral therapy (ART) for HIV-1-infected individuals prevents sexual transmission if viral load is suppressed. Methods: Participants were HIV-1-infected partners randomized to early ART (CD4 350-550) in HPTN052 (n 886, median follow-up 2.1 years), a clinical trial of early ART to prevent sexual transmission of HIV-1 in serodiscordant couples at 13 sites in 9 countries. Adherence was assessed through pill count (dichotomized at

Original languageEnglish (US)
Pages (from-to)234-240
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume69
Issue number2
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

    Fingerprint

Keywords

  • adherence
  • ART for prevention
  • treatment as prevention

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Safren, S., Mayer, K. H., Ou, S. S., McCauley, M., Grinsztejn, B., Hosseinipour, M. C., Kumarasamy, N., Gamble, T., Hoffman, I., Celentano, D., Chen, Y. Q., & Cohen, M. S. (2015). Adherence to early antiretroviral therapy: Results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. Journal of Acquired Immune Deficiency Syndromes, 69(2), 234-240. https://doi.org/10.1097/QAI.0000000000000593